one and 399 were allocated to the control group. Baseline characteristics were similar. In the IVT subgroup, preventive ceftriaxone was associated with a significant reduction in unfavorable outcome (adjusted common OR 0.77; 95% CI 0.61-0.99; p = 0.04). Mortality at 3 months was similar (OR 0.75; 95% CI 0.48-1.18). Preventive ceftriaxone was associated with a reduction in infections (OR 0.43; 95% CI 0.28-0.66), and a trend towards an increased risk for sICH (OR 3.09; 95% CI 0.85-11.31). Timing of ceftriaxone administration did not influence the outcome (aOR 1.00; 95% CI 0.98-1.03; p = 0.85). Conclusions: According to the post-hoc analysis of PASS, preventive ceftriaxone may improve the functional outcome in IVT-treated patients with acute stroke, despite a trend towards an increased rate of post-IVT-sICH.
Introduction
Infection is a common complication in the acute phase after stroke [1] . In a recent meta-analysis of 87 studies, the pooled infection rate after stroke was 30%; most commonly pneumonia and urinary tract infections [2] . Many studies have shown that the occurrence of infections after stroke is associated with a poor functional outcome and mortality [3] , although there are some reports suggesting that an infection after stroke is merely a marker of stroke severity without an independent effect on outcome when it is treated promptly [4] .
Previously, 6 randomized studies had assessed the preventive use of antimicrobials in patients with acute stroke, with conflicting results [5] [6] [7] [8] [9] [10] . A Cochrane meta-analysis including 506 patients from 5 studies concluded that although studies differed in populations analyzed, type of antimicrobial used, and definition of infection, overall antimicrobial prophylaxis reduced the infection rate from 36 to 22% (relative risk 0.58; 95% CI 0.43-0.79) without any major adverse effects. Whether or not preventive antimicrobials reduced the risk of poor functional outcome after stroke remained uncertain: the overall mortality rate was non-significantly reduced from 15% in the placebo group to 13% (95% CI 0.47-1.51), and the number of dependent patients was reduced from 61 to 47% (95% CI 0.32-1.43) [3] .
Recently, results of the Preventive Antibiotics in Stroke Study (PASS) were published, a pragmatic randomized open-label masked endpoint clinical trial investigating the efficacy and safety of the preventive use of the β-lactam antibiotic ceftriaxone in patients with acute stroke [10] [11] [12] . A total of 2,550 patients from 30 sites in The Netherlands, including academic and non-academic medical centers, were randomly assigned to 2 treatment groups: 1,275 patients to ceftriaxone and 1,275 patients to standard treatment (control group). Preventive ceftriaxone did not improve the functional outcome at 3 months after stroke (adjusted common OR 0.95; 95% CI 0.82-1.09). Post-hoc analyses showed that in the patients who received intravenous thrombolysis (IVT) with alteplase, unfavorable outcomes occured significantly less frequent in patients who received ceftriaxone as compared with the control group. This study aimed to gain more insight into the characteristics of the patients treated with IVT.
Methods
We performed a post-hoc analysis of patients in PASS who received IVT with alteplase (IVT-patients). In PASS, patients were randomly assigned in a 1: 1 ratio for treatment with ceftriaxone in addition to stroke unit care, or to standard stroke unit care without preventive antimicrobial therapy. Details of the study design, procedures, outcome measurements and statistical analysis have been published [11] [12] [13] . The study was registered with controlled-trials. com, number ISRCTN66140176. Participating centres are mentioned in the appendix.
Patients were eligible for inclusion if they were aged 18 years or older, had clinical symptoms of a stroke (ischemic or hemorrhagic), an onset of symptoms less than 24 h, and a score of 1 or more on the National Institutes of Health Stroke Scale (NIHSS). Exclusion criteria included clinical signs of infection on hospital admission requiring antibiotic therapy, use of antimicrobials less than 24 h before admission, pregnancy, hypersensitivity for cephalosporins, previous anaphylaxis for penicillin derivatives, subarachnoid hemorrhage, and imminent death.
Preventive antibiotics were initiated within 24 h after the onset of symptoms. The study medication was ceftriaxone 2 g, given intravenously once daily for 4 days. Ceftriaxone was discontinued in patients who were either discharged or in whom active treatment was withdrawn. The treating clinician could decide whether or not to treat a patient with suspected infection with (additional) antimicrobials. Study procedures with respect to antimicrobial treatment are detailed in the study protocol [11, 12] .
The primary outcome was functional status at 3 months, defined by the modified Rankin Scale (mRS), which ranges from 0 (no symptoms) to 6 (death). Secondary outcomes were death at discharge and 3 months after randomization, infection rate, total antimicrobial use, length of hospital stay, volume of post-stroke care, and quality-adjusted life-years and costs. Infections were categorized as diagnosed by the clinician, and as judged by an independent adjudication committee (masked to treatment allocation) according to modified Centers for Disease Control and Prevention criteria.
In the current post-hoc analysis, an interaction analysis, comparing thrombolysis with study allocation (ceftriaxone vs. standard care), was performed first. Functional status was assessed by comparing IVT patients with non-IVT patients (patients in PASS 'who potentially could have been treated with IVT, given their diagnosis: 'infarct', 'TIA' or 'other'; a total of 1,433 patients').
Next, among the IVT patients, the functional status was assessed according to study allocation, both by ordinal regression of the entire range (0-6) of the mRS score at 3 months and by a dichotomized outcome (favorable (mRS 0-2) vs. unfavorable (mRS 3-6)). Secondary outcomes were death at discharge and at 3 months after randomization, infection rate during admission and symptomatic intracerebral hemorrhage (sICH) rate as a safety outcome. Cause of death during admission was retrieved from the hospital discharge letters and patient records. Causes were categorized according to the most frequently observed etiology.
To investigate if an earlier timing of administration of ceftriaxone in IVT patients was associated with an outcome, the time between the onset of symptoms and the administration of the first gift of ceftriaxone and its effect on functional outcome was calculated.
Tests of group differences were performed by using standard methods depending on the type of variable. Normal and non-normal distributed variables were compared with the Student's t test and the Mann-Whitney U test. For the ordinal regression model, both unadjusted and adjusted analyses were performed. Adjustment variables were defined beforehand and included age, stroke severity as defined by NIHSS score, history of stroke, history of diabetes, previous disability as defined on the mRS, stroke type and categorization of study center. Two-tailed p values <0.05 were identified to indicate statistical significance.
Interaction Analysis
In PASS, unplanned post-hoc dichotomous analyses showed that in patients who received IVT with alteplase (IVT-group) unfavorable outcomes occurred in 144 (33%) of the 437 patients who received ceftriaxone compared with 160 (40%) of 399 in the control group (aOR 0.77; 95% CI 0.61-0.99; p = 0.04) [10] . Including all patients, the p value for the interaction between IVT with alteplase and preventive ceftriaxone on functional outcome was 0.03.
The proportion of patients with a history of atrial fibrillation, hypertension, cardiac valve disease or obstructive pulmonary disease was higher in the non-IVT group compared to the IVT group (online suppl. table I; for all online suppl. material, see www.karger.com/doi/10.1159/ 000446160), as was the case when comparing 'ceftriaxone and IVT-treated' with 'ceftriaxone and non-IVT-treated patients' (online suppl. table II).
There were no differences in the functional outcome or infection rate except for urinary tract infections, which was diagnosed more often in non-thrombolyzed patients when comparing the IVT group with the non-IVT group ( table 1 ) .
When adjusting for the observed differences in baseline characteristics, no differences were found when comparing 'ceftriaxone and IVT-treated' with 'ceftriaxone and non-IVT-treated patients'. As expected, a better outcome was observed in IVT-treated patients as compared with non-IVT-treated patients (online suppl. table III).
Baseline Characteristics and Stroke Outcome
The baseline demographic and clinical characteristics according to the study allocation within the IVT group were similar, although in the ceftriaxone group more patients were on angiotensin converting enzyme inhibitors and the median systolic blood pressure at presentation was slightly lower ( table 2 ). The definite diagnosis was a cerebral infarction in 806 cases (96%), TIA in 10 patients (1%), and an alternative diagnosis in 20 patients (2%). Alternative diagnoses were functional neurological symptoms in 10, multiple sclerosis in 3, * Data are n/N (%) or median (IQR). NA = Not applicable. ** Non-IVT group is considered the population in PASS that could potentially have been treated with IVT, given their diagnosis: 'infarct', 'TIA' or 'other'.
† Predefined adjustment included age, stroke severity as defined by NIHSS score, history of stroke, history of diabetes, previous disability as defined on the mRS, stroke type, and categorization of study centre.
§ Unfavorable outcome was defined on the mRS: a score of 0-2, indicating a favorable outcome, vs. a score of 3-6, indicating an unfavorable outcome. and migraine, epilepsy, vestibulopathy, cervical myelopathy each in one; in 3 patients the definitive diagnosis was lacking due to diagnostic uncertainty by the neurologist.
Preventive ceftriaxone was associated with a significant shift towards a better functional outcome at 3 months (unadjusted common OR 0.75; 95% CI 0.59-0.96; p = 0.02). After adjustment for stroke severity, age, history of diabetes or previous stroke, mRS on baseline and type of hospital, the beneficial effect remained, as mentioned earlier ( fig. 1 ). In the dichotomized analysis of mRS, preventive ceftriaxone was associated with a significant reduction in the risk of an unfavorable outcome (144 (33%) vs. 160 (40%); OR 0.73; 95% CI 0.55-0.97). There was no significant difference in mortality between the two treatment groups after discharge (21 (5%) vs. 23 (6%); OR 0.83; 95% CI 0.45-1.52) or after 3 months (39 (9%) vs. 46 (12%); OR 0.75; 95% CI 0.48-1.18) ( table 3 ) .
Effect of Preventive Ceftriaxone on Infections
Among the IVT patients, patients in the ceftriaxone group were significantly less frequently diagnosed with an infection as compared with the control group (34 (8%) vs. 66 (17%); OR 0.43; 95% CI 0.28-0.66). This difference Symptomatic Intracerebral Hemorrhage sICH developed in 15 of 836 (1.8%) IVT patients during hospital admission, of which 13 within 48 h after the onset of symptoms (defined as post-IVT-sICH). Although non-significantly, preventive ceftriaxone was associated with the development of post-IVT-sICH (10 of 437 (2.3%) vs. 3 of 399 (0.8%); OR 3.09; 95% CI 0.85-11.31). * Data are n/N (%) or median (IQR). NA = Not applicable. † Predefined adjustment included age, stroke severity as defined by NIHSS score, history of stroke, history of diabetes, previous disability as defined on the mRS, stroke type, and categorization of study centre.
‡ Post-hoc adjustment included predefined adjustment parameters plus prior use of an ACE inhibitor. § Unfavorable outcome was defined on the mRS: a score of 0-2, indicating a favorable outcome, vs. a score of 3-6, indicating an unfavorable outcome. 
Cause of Death
The cause of death was categorized for all 44 IVT patients who died within follow-up time of the study. Median time between admission and death was 5 days in both the intervention and control groups. Patients in the ceftriaxone group tended to die significantly more often of post-IVT-sICH (7 of 21 (33%) vs. 2 of 23 (9%); p = 0.06), whereas patients in the control group died more often of infection (9 of 23 (39%) vs. 0 patients; p = 0.002). Other causes of death were more or less equally distributed between both groups ( table 4 ).
Effect of Early Treatment with Ceftriaxone on Stroke Outcome
IVT patients received ceftriaxone earlier compared to non-IVT patients (median 8 vs. 12 h). Considering the current 'treatment window', a timeframe of 6 h after onset of symptoms, 171 of 414 (41%) IVT patients received ceftriaxone vs. 122 of 648 (19%) non-IVT patients (p < 0.001). The timing of administration of ceftriaxone in thrombolyzed vs. non-thrombolyzed patients did not influence stroke outcome after 3 months in an adjusted ordinal regression model (aOR 1.00; 95% CI 0.98-1.03; p = 0.85).
Discussion
This post-hoc analysis of the PASS suggests that preventive antimicrobial therapy with ceftriaxone in IVT patients with acute stroke diminishes the number of infections and improves the functional outcome despite a trend towards an increased rate of post-IVT-sICH. Whether or not treatment with preventive ceftriaxone provides benefit in patients with acute ischemic stroke treated with IVT remains to be confirmed [14] .
Overall, in the entire study cohort of 2,550 patients in PASS, preventive antimicrobial therapy did neither improve functional outcome, nor was the length of hospital stay shortened or was the in-hospital or follow-up mortality reduced. Prophylaxis with ceftriaxone, however, did significantly decrease the infection rate and had a favorable safety profile. The only subgroup in which an effect on functional outcome could be shown, -in a post-hoc analysis-, was the group of patients with acute ischemic stroke who were treated with IVT.
We would like to emphasize that the patient population in the current analysis slightly differs from the population of the entire PASS. Of the 2,538 patients used in the original intention-to-treat analysis, 269 patients suffering from cerebral hemorrhage were excluded. The remaining 2,269 patients could potentially have been treated with IVT, given their diagnosis: 'infarct', 'TIA' or 'other'. Since risk factors between intracerebral infarction and hemorrhage differ, slight differences in baseline characteristics between the original population and current subgroup analysis are possible. These differences could indeed be observed when comparing IVTtreated patients (n = 836) with non-IVT-treated patients (n = 1,433; online suppl. table I) and when comparing 'ceftriaxone and IVT-treated patients' (n = 437) with 'ceftriaxone and non-IVT-treated patients' (n = 688) (online suppl. table II): IVT-treated patients more often had a history of atrial fibrillation, hypertension, cardiac valve disease, or obstructive pulmonary disease. These differences are considered a finding by chance, since prior history is not considered when making the decision for thrombolysis in the acute phase in the emergency room. These differences in baseline characteristics did not influence the functional outcome (online suppl. table III).
For the observed beneficial effect of ceftriaxone in IVT patients with acute stroke, several possible explanations are available.
First, the effect could have been due to chance. Posthoc observations should be interpreted with care irrespective of their statistical significance, and the current study design therefore remains the most important limitation of the study, as will be discussed later [14] . However, there are several reasons to believe the observed effect could be real. Despite the finding that, as compared with the total population in PASS (n = 2,550), the absolute risk reduction of infection when comparing 'preventive antimicrobial therapy' with 'no antimicrobial therapy', is slightly higher in the IVT-treated subgroup (n = 836), it seems unlikely that only this would explain the observed treatment effect since differences are small and more subgroup analyses in PASS would likely have shown the treatment effect. Whilst in the intervention arm in PASS, ceftriaxone reduced the proportion of patients with poststroke infection from 18 to 10%, current reduction ranged from 17 to 8%. This effect is also more pronounced for the incidence of pneumonia, which in PASS was reduced from 7 to 6%, as compared with a reduction from 7 to 4% in IVT patients. As a local inflammatory response within the central nervous system is implicated in secondary growth of the ischemic brain lesion and systemic immune alterations are rapidly induced by ischemic stroke, infections in the immediate post-stroke period are associated with increased morbidity and mortality [15] . However, if only the prevention of infection during admission and the subsequent decreased inflammatory response would explain the observed treatment effect; very likely more subgroup analyses within PASS, for example, the comparison of IVT vs. non-IVT patients, would have shown beneficial effects of preventive ceftriaxone.
Another possible explanation for the observed treatment effect is a possible interaction between ceftriaxone and alteplase that might enlarge the effect of both drugs. The observed trend towards an increased rate of post-IVT-sICH in ceftriaxone-treated patients might in this case be an indication. As for pharmacokinetics, a dosedependent effect of alteplase on stroke outcome has been shown in different studies with significant higher rates of ICH rate with doses above 0.95 mg/kg, which has led to a licensed dose for administration of 0.9 mg/kg body weight [16] . The drug is predominantly metabolized by the liver and is eliminated via urine [16] , as is ceftriaxone [17] . However, to date no data comparing both pharmacokinetic profiles have been published. As for pharmacodynamics, in polymerized ampicillin, another beta-lactam antibiotic, a dose-dependent inhibition of the fibrinolytic activity of plasminogen has been shown in one in vitro study [18] . Ceftriaxone might also interact directly with coagulation: the antibiotic showed weak compatibility with platelets, as revealed by enhanced platelet aggregation and thromboxane A 2 production in an in vitro study; prostacyclin production and t-PA release were inhibited [19] .
Ceftriaxone also has neuroprotective properties that might explain its beneficial effect on stroke outcome [20] . However, this would not explain why the beneficial effect is limited to IVT-treated patients; except when ceftriaxone and alteplase again show an interaction. In vitro and rodent studies have shown that the beta-lactam antibiotic appears to increase the glutamate transporter activity (glutamate transporter 1) that is normally reduced following stroke, leading to the release of (neurotoxic) glutamate into the extracellular space and eventually neuronal loss by excitotoxicity [21] [22] [23] [24] . Alteplase itself can also influence the glutamate transporter activity. A rodent model for stroke showed that t-PA amplifies the downregulation of the glutamate transporter, independent of cerebral ischemia [25] . Another hypothesis for neuroprotection could be through matrix metalloproteinases (MMPs) [26] [27] [28] . For the tetracycline antibiotic minocycline, a reduction in MMPs has been shown, both in vitro and in vivo, with a decrease in infarct size and a 2-fold decrease in post-IVT-sICH [26] [27] [28] [29] [30] . To date, however, little is known about possible interactions between ceftriaxone and MMPs since current experiments are mainly on rodent models of meningitis experimenting the effect of other MMP inhibitors (e.g. Ro 32-3555 or GM6001) on neuronal loss or learning abilities with ceftriaxone only as a comedication [31] [32] [33] [34] [35] [36] [37] . Since studies on minocycline show a 2-fold decrease and ceftriaxone in current analysis showed a 3-fold increase in post-IVT-sICH rate, an identical effect of ceftriaxone on MMPs seems unlikely.
As mentioned earlier, the most important limitation of this study is the fact that current findings are based on an unplanned post-hoc analysis. The observed treatment effect might, therefore, be purely based on chance [38] : with increasing numbers of subgroup analyses with a p value of 0.05, the probability increases that one or more findings by chance arise that may consequently be misinterpreted as clinically directive (false positive result) [39] . However, despite the consideration that post-hoc analysis may lead to overstated and misleading results [40] , current observed treatment effect remains present after adjustment for multiple possible confounders and might therefore be genuinely caused by a treatment effect.
Since our findings are based on a post-hoc analysis, further research needs to be done before applying preventive ceftriaxone after thrombolysis in everyday practice. teraction was observed between preventive antibiotics and IVT for functional outcome at 90 days (aOR 0.60; 95% CI 0.33-1.09; p = 0.097) [41] . A pooled analysis is planned combining both studies, with particular emphasis on predefined subgroups, among which are IVT-treated patients. Simultaneously, more preclinical trials are required to gain more insight into the pharmacokinetic and -dynamic effects of ceftriaxone on alteplase.
Summary
This post-hoc analysis of PASS suggests that preventive ceftriaxone may improve the functional outcome in IVT-treated patients with acute stroke, despite a trend towards an increased rate of post-IVT-sICH.
